%0 Journal Article
%A Krämer, P
%A Talhouk, A
%A Brett, MA
%A Chiu, DS
%A Cairns, ES
%A Scheunhage, DA
%A Hammond, RF
%A Farnell, D
%A Nazeran, TM
%A Grube, M
%A Xia, Z
%A Senz, J
%A Leung, S
%A Feil, L
%A Pasternak, J
%A Dixon, K
%A Hartkopf, A
%A Krämer, B
%A Brucker, S
%A Heitz, F
%A du Bois, A
%A Harter, P
%A Kommoss, F
%A Sinn, H-P
%A Heublein, S
%A Kommoss, F
%A Vollert, H-W
%A Manchanda, R
%A de Kroon, CD
%A Nijman, HW
%A de Bruyn, M
%A Thompson, EF
%A Bashashati, A
%A McAlpine, JN
%A Singh, N
%A Tinker, AV
%A Staebler, A
%A Bosse, T
%A Kommoss, S
%A Köbel, M
%A Anglesio, MS
%D 2020
%F discovery:10106983
%J Clinical Cancer Research
%N 20
%P 5400-5410
%T Endometrial Cancer Molecular Risk Stratification is Equally Prognostic for Endometrioid Ovarian Carcinoma
%U https://discovery.ucl.ac.uk/id/eprint/10106983/
%V 26
%X Purpose: Endometrioid ovarian carcinoma (ENOC) is generally associated with a more favorable prognosis compared to other ovarian carcinomas. Nonetheless, current patient treatment continues to follow a "one-size-fits-all" approach. Even though tumor staging offers stratification, personalized treatments remain elusive. As ENOC shares many clinical and molecular features with its endometrial counterpart, we sought to investigate TCGA-inspired endometrial cancer (EC) molecular subtyping in a cohort of ENOC. Experimental Design: Immunohistochemistry and mutation biomarkers were used to segregate 511 ENOC tumors into four EC-inspired molecular subtypes: low-risk POLE mutant (POLEmut); moderate-risk mismatch repair deficient (MMRd); high-risk p53 abnormal (p53abn); moderate-risk with no specific molecular profile (NSMP). Survival analysis with established clinicopathological and subtypes specific features was performed. Results: 3.5% of cases were POLEmut, 13.7% MMRd, 9.6% p53abn and 73.2% NSMP, each showing distinct outcomes (p <0.001) and survival similar to observations in EC. Median OS was 18.1 years in NSMP, 12.3 years in MMRd; 4.7 years in p53abn and not reached for POLEmut cases. Subtypes were independent of stage, grade, and residual disease in multivariable analysis. Conclusions: EC-inspired molecular classification provides independent prognostic information in ENOC. Our findings support investigating molecular-subtype specific management recommendations for ENOC patients; for example, subtypes may provide guidance when fertility-sparing treatment is desired. Similarities between ENOC and EC suggest that ENOC patients may benefit from management strategies applied to EC and the opportunity to study those in umbrella trials.
%Z This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions.